Skip to main content
ALKS $49.06 -0.79%
ALKS logo

ALKS · Alkermes plc.

Track ALKS — free
$49.06 -0.39 (-0.79%) At close · Aug 14
Market Cap
$8.23B
Shares
167.76M
All earnings calls

Earnings call · FY2026 Q2

Q2 2026 Alkermes plc Earnings Conference Call

Q2 2026 Alkermes plc Earnings Conference Call

Concluded Jul 28, 2026
Jul 28, 2026 0 turns
Period
FY2026 Q2
Runtime
Sources
2 artifacts

Executive readout · one minute

Call research workspace

Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.

Forward guidance

15 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $496.01M +27% YoY
Diluted EPS $0.00 -100% YoY
Net income $501,000 -99.4% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Forward guidance

From the 8-K filed Jul 28, 2026.

Metric Guided
Total Revenues table
2026 Expectations
$1.73B – $1.84B
VIVITROL Net Sales table
2026 Expectations
$460M – $480M
ARISTADA Net Sales table
2026 Expectations
$365M – $385M
LYBALVI Net Sales table
2026 Expectations
$380M – $400M
Cost of Goods Sold table
2026 Expectations
$320M – $340M
LUMRYZ Net Sales table
Feb. 12, 2026 – Dec. 31, 2026
$315M – $335M
R&D Expenses table
2026 Expectations
$445M – $485M
SG&A Expenses table
2026 Expectations
$890M – $930M
Amortization of Intangible Assets table
2026 Expectations
$75M – $85M
Change in the Fair Value of Contingent Consideration table
2026 Expectations
$25M
Net Tax Benefit table
2026 Expectations
$0
Net Interest Expense table
2026 Expectations
$75M – $85M
GAAP Net Loss table
2026 Expectations
$-115M – $-95M
EBITDA table
2026 Expectations
$75M – $95M
Adjusted EBITDA table
2026 Expectations
$370M – $410M

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

Vivitrol$124.45M +2.3% YoY
Aristada and Aristada Initio$96.72M -4.5% YoY
LUMRYZ$96.57M
LYBALVI$93.98M +11.5% YoY
Royalty$63.38M -5.2% YoY
Manufacturing Revenue$20.90M +26.2% YoY
Full-screen source Call document